ACM
ABEO icon

Altium Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Altium Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-108,696
Closed -$335K – 91
2022
Q4 		$335K Buy
+108,696
New +$407K 0.17% 62

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Altium Capital Management's ABEO Position: Q1 2023 in Review

Altium Capital Management sold out of Abeona Therapeutics (ABEO) in Q1 2023, closing a stake of 108,696 shares — an estimated $335K sold.

Altium Capital Management first reported a position in ABEO in Q4 2022 and held it in 1 quarter. The position peaked at $335K in Q4 2022. 33 funds tracked by Wall St. Rank hold ABEO as of Q1 2023.

  • Altium Capital Management reported no remaining Abeona Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Altium Capital Management sold 108,696 Abeona Therapeutics shares in Q1 2023, an estimated $335K.
  • Altium Capital Management first reported a position in Abeona Therapeutics in Q4 2022 and held it in 1 quarter.
  • Altium Capital Management's Abeona Therapeutics position peaked at $335K in Q4 2022.
  • 33 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2023.

Based on Altium Capital Management's 13F filing for Q1 2023, filed 15 May 2023.